SPRUCE BIOSCIENCES, INC.
SPRB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SPRB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRB
Spruce Biosciences is a biopharmaceutical company developing TA-ERT, a therapy for MPS IIIB, with a Phase 3 trial underway and a cash runway through mid-2027.
Key risk: Clinical trial failure
BioSniper Score
Based on 5 of 6 signals
Market Cap
$174.7M
Cash Runway
—
Lead Asset
spr202 (Preclinical)
Next Catalyst
Phase3_Topline · Aug 1, 2033Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 8 clinical trials · 1 catalyst for SPRUCE BIOSCIENCES, INC..
Spruce Biosciences is a biopharmaceutical company developing TA-ERT, a therapy for MPS IIIB, with a Phase 3 trial underway and a cash runway through mid-2027.
- Spruce Biosciences is a biopharmaceutical company focused on developing TA-ERT for MPS IIIB [sec_mda].
- As of 2026-06-30, the company reported cash & equivalents of $96.3M, net income of -$16.2M, shareholders' equity of $13.2M, and total debt of $22.4M [sec].
- The company expects its cash and proceeds from the August 2026 private placement to fund operations and debt obligations for at least 12 months from the issuance date of the financial statements [sec_mda · as of 2026-08-12].
- Spruce is pursuing regulatory approval of TA-ERT for MPS IIIB and plans to build a commercial organization in the U.S. if approved [sec_mda · as of 2026-08-12].
- The company has a Phase 3 trial for TA-ERT with a topline data readout expected on 2033-08-01 [catalyst].
What works
- Spruce has a clear regulatory pathway for TA-ERT in MPS IIIB, with ongoing Phase 3 trial and plans for commercialization in the U.S. [sec_mda · as of 2026-08-12].
- The company has raised capital through public offerings and private placements, with cash of $96.3M as of 2026-06-30 providing a runway of at least 12 months [sec] [sec_mda · as of 2026-08-12].
- Spruce is seeking strategic collaborations to leverage resources from specialized biopharmaceutical companies for markets outside the U.S. [sec_mda · as of 2026-08-12].
What to weigh
- The company has a history of operating losses, with a net loss of $16.2M for the quarter ended 2026-06-30 and an accumulated deficit [sec] [sec_mda].
- Spruce faces significant uncertainty in the timing and cost of completing development and obtaining regulatory approval for TA-ERT [sec_mda · as of 2026-05-13].
- The company's cash runway is dependent on successful fundraising and may be insufficient if expenses increase or milestones are delayed [sec_mda · as of 2026-08-12].
- Spruce has no approved products and relies solely on the success of TA-ERT, which is still in clinical development [sec_mda].
From the filings
Quoted directly from source documents.
Spruce is a biopharmaceutical company developing TA-ERT for MPS IIIB.
“We are a biopharmaceutical company”
SEC MD&A · November 10, 2025
Cash and proceeds from August 2026 private placement are expected to fund operations for at least 12 months.
“30, 2026 and the proceeds from the August 2026 private placement will be sufficient to fund our planned operations and debt obligations for at least 12 months following the issuance date of these financial statements”
SEC MD&A · August 12, 2026
Spruce plans to pursue regulatory approval and commercialize TA-ERT in the U.S.
“pursue regulatory approval of TA-ERT in patients with MPS IIIB; • build a highly specialized commercial organization to support the commercialization of TA-ERT, if approved, in the United States”
SEC MD&A · August 12, 2026
The company cannot estimate the timing or cost of completing development of TA-ERT.
“we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, TA-ERT”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2033-08-01 · Phase3_Topline — Topline data from the Phase 3 trial of TA-ERT for MPS IIIB will be released, which is a key milestone for determining efficacy and safety.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — TA-ERT may fail in Phase 3 trials, leading to no approved product and loss of investment [sec_mda].
- Regulatory delay or denial — Regulatory approval for TA-ERT is uncertain and may be delayed or denied, impacting commercialization [sec_mda].
- Cash runway dependency — Cash runway depends on successful fundraising; if expenses rise or milestones slip, funding may be insufficient [sec_mda · as of 2026-08-12].
- Single product focus — Spruce relies solely on TA-ERT; any setback could severely impact the company's viability [sec_mda].
What to watch
- Phase 3 topline data for TA-ERT expected on 2033-08-01 [catalyst].
- Regulatory submissions and updates on TA-ERT approval process [sec_mda · as of 2026-08-12].
- Cash burn rate and any additional financing activities [sec].
- Progress on strategic collaborations for ex-U.S. markets [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run SPRUCE BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SPRUCE BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.23 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~2528d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$38.3M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 111,888 | $7.3M |
| citadel advisors llc | 69,999 | $4.6M |
| adar1 capital management, llc | 58,600 | $3.8M |
| alyeska investment group, l.p. | 51,671 | $3.4M |
| wellington management group llp | 48,796 | $3.2M |
| boothbay fund management, llc | 42,080 | $2.7M |
| balyasny asset management l.p. | 40,000 | $2.6M |
| quinn opportunity partners llc | 26,810 | $1.8M |
| exoduspoint capital management, lp | 22,000 | $1.4M |
| vanguard capital management llc | 18,337 | $1.2M |
Showing top 10 of 30 institutional holders of SPRUCE BIOSCIENCES, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 13.4%
- Days to cover
- 3.4
- Shares short
- 180,537
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRB short interestGovernance
Frequently asked questions
What is the AI investment thesis for SPRUCE BIOSCIENCES, INC.?
Spruce Biosciences is a biopharmaceutical company developing TA-ERT, a therapy for MPS IIIB, with a Phase 3 trial underway and a cash runway through mid-2027.
What is SPRUCE BIOSCIENCES, INC.'s lead drug candidate?
SPRUCE BIOSCIENCES, INC.'s most advanced tracked candidate is spr202 (Preclinical) for Congenital Adrenal Hyperplasia (CAH).
What is SPRUCE BIOSCIENCES, INC.'s next catalyst?
SPRUCE BIOSCIENCES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the S" — expected August 1, 2033.
Who is the CEO of SPRUCE BIOSCIENCES, INC.?
Dr. Javier Szwarcberg M.D., M.P.H. is the chief executive officer of SPRUCE BIOSCIENCES, INC. (SPRB).
Where is SPRUCE BIOSCIENCES, INC. headquartered?
SPRUCE BIOSCIENCES, INC. (SPRB) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.